MedDataX Logo

Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC)

NCT ID: NCT00880711

Last Updated: 2011-11-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

57 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-04-30

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose is to collect real life data on the use of fulvestrant in normal clinical practice in Austria and document the clinical benefit of fulvestrant treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Fiona Faslodex Advanced Breast Cancer Real life data Collect real life data in clinical practice across Austria

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Patient with advanced BC, already receiving Faslodex therapy

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer
* Ability to read and write and complete questionnaires
* Provision of written informed consent
* Patients who already received a prescription for fulvestrant
Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Guenther Steger, Univ Prof. Dr.

Role: STUDY_CHAIR

Medical University of Vienna

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Graz, , Austria

Site Status

Research Site

Innsbruck, , Austria

Site Status

Research Site

Klagenfurt, , Austria

Site Status

Research Site

Leoben, , Austria

Site Status

Research Site

Linz, , Austria

Site Status

Research Site

Oberpullendorf, , Austria

Site Status

Research Site

Rankweil, , Austria

Site Status

Research Site

Rottenmann, , Austria

Site Status

Research Site

Salzburg, , Austria

Site Status

Research Site

Sankt Veit im Pongau, , Austria

Site Status

Research Site

Steyr, , Austria

Site Status

Research Site

Vienna, , Austria

Site Status

Research Site

Wiener Neustadt, , Austria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-OAT-FAS-2009/1

Identifier Type: -

Identifier Source: org_study_id